Semin Perinatol by Olney, Richard S. et al.
Detection of critical congenital heart defects: Review of 
contributions from prenatal and newborn screening
Richard S. Olney, MD, MPHa,*, Elizabeth C. Ailes, PhD, MPHa, and Marci K. Sontag, PhDb
aNational Center on Birth Defects and Developmental Disabilities, Centers for Disease Control 
and Prevention (CDC), 1600 Clifton Rd, Mailstop E86, Atlanta, GA 30333
bDepartment of Epidemiology, Colorado School of Public Health at University of Colorado Denver 
at Anschutz Medical Campus, Aurora, CO
Abstract
In 2011, statewide newborn screening programs for critical congenital heart defects began in the 
United States, and subsequently screening has been implemented widely. In this review, we focus 
on data reports and collection efforts related to both prenatal diagnosis and newborn screening. 
Defect-specific, maternal, and geographic factors are associated with variations in prenatal 
detection, so newborn screening provides a population-wide safety net for early diagnosis. A new 
web-based repository is collecting information on newborn screening program policies, quality 
indicators related to screening programs, and specific case-level data on infants with these defects. 
Birth defects surveillance programs also collect data about critical congenital heart defects, 
particularly related to diagnostic timing, mortality, and services. Individuals from state programs, 
federal agencies, and national organizations will be interested in these data to further refine 
algorithms for screening in normal newborn nurseries, neonatal intensive care settings, and other 
special populations; and ultimately to evaluate the impact of screening on outcomes.
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Introduction
In this review, we define critical congenital heart defects (CCHD) as structural 
malformations of the heart that are present at birth and require intervention in the first year 
of life, and we focus on prenatal and postnatal screening for CCHD in the United States 
(U.S.). Seven categories of CCHD that usually present in newborns with hypoxemia were 
considered by the Secretary of Health and Human Service’s Advisory Committee on 
Heritable Disorders in Newborns and Children (SACHDNC) as the primary targets for pulse 
oximetry screening.1 These seven types are (1) dextro-transposition of the great arteries; (2) 
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hypoplastic left heart syndrome; (3) pulmonary atresia (with intact ventricular septum); (4) 
tetralogy of Fallot; (5) total anomalous pulmonary venous return; (6) tricuspid atresia; and 
(7) truncus arteriosus. The National Birth Defects Prevention Network (NBDPN), an 
organization of state and population-based birth defects programs partially funded by the 
Centers for Disease Control and Prevention (CDC), has developed case definitions for these 
primary targets.2 These definitions include inclusion and exclusion terminology for each 
category of defects, coding lists to be used by birth defects programs for ascertainment of 
records from population-based sources, and diagnostic criteria used in reviewing records of 
prenatally and postnatally diagnosed defects. Other types of CCHD that sometimes present 
with hypoxemia and are considered “secondary targets” include critical aortic coarctation, 
atresia/hypoplasia/interruption of the aortic arch, double outlet right ventricle, Ebstein 
anomaly, severe aortic valve stenosis, severe pulmonic stenosis, and single ventricle 
complex.3
Public health importance of CCHD and early detection
The importance of CCHD in the perinatal context results from the frequency of detection in 
both prenatal and neonatal settings, the necessity of early detection to prevent complications, 
and the contribution of these defects to infant mortality. Practicing maternal-fetal medicine 
specialists and neonatologists are well aware of the impact of malformations in general, and 
practitioners are involved with many of the approximately 3% of newborns affected with 
birth defects. Nearly 1% of newborns have congenital heart defects, and approximately one-
quarter of those defects are in the CCHD category.4-6 Some newborns with CCHD will have 
obvious clinical signs in the nursery, but since a subset of affected infants depend on 
circulation through the ductus arteriosus, closure of the ductus after nursery discharge can be 
catastrophic and is a major impetus for hospital-based screening in order to avoid 
unexpected deaths. Congenital heart disease has been reported to be responsible for 30–50% 
of infant mortality due to birth defects, and from 1999 to 2006 (before the advent of CCHD 
newborn screening), more than 13,000 infant deaths resulting from congenital heart defects 
were reported in the U.S.7 These deaths occurred most commonly with diagnoses of 
hypoplastic left heart syndrome, transposition of the great arteries, or tetralogy of Fallot, in 
that order of severity, and these three types of CCHD (in reverse order of reported 
frequency) also have the highest rates among live births in NBDPN surveillance data (Fig.).
In spite of the relatively common occurrence of CCHD among children with birth defects 
and the adverse consequences they have for cardiac physiology, newborns are often 
unsuspected of having CCHD before transitional events from fetal circulation occur. Cardiac 
defects might not be suspected if there is no multiple malformation syndrome, no prenatal 
cardiac diagnoses by screening ultrasound and/or fetal echocardiography (discussed below), 
or in the absence of any family history that would alert parents and providers about the need 
to investigate for CCHD. Among infants with any congenital heart defect, conventional 
cytogenetic abnormalities such as trisomies have only been reported in approximately one-
tenth of those affected.8,9 In isolated CCHD, physical examination might not detect cyanosis 
or other clinical signs before transitions from fetal circulation are completed, which can 
occur after nursery discharge.
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Implementing CCHD newborn screening in the United States
Statewide newborn screening for CCHD has developed rapidly after a series of events in 
recent years. Pilot screening programs for subclinical cyanosis related to CCHD had been 
reported from normal newborn nurseries in the U.S. for more than 10 years.10 The 
centerpiece of these early programs was pulse oximetry, already with a well-established 
presence in hospitals for noninvasive hypoxemia screening. As pilot data accumulated 
internationally, in 2009 the American Heart Association (AHA) and the American Academy 
of Pediatrics (AAP) published a scientific statement reviewing pulse oximetry screening 
studies with recommendations for larger and more diverse studies.3 This statement and other 
published data such as a prospective study from Sweden led to considerations for 
population-based screening implementation.11 After further evidence reviews in 2010–2011, 
the U.S. Secretary of Health and Human Services adopted the SACHDNC’s endorsement of 
CCHD screening for the Recommended Uniform Screening Panel (RUSP) for newborns. 
Subsequently, an expert panel published an algorithm for pulse oximetry screening that was 
endorsed by the AAP, AHA, and the American College of Cardiology (ACC).1,12,13
U.S. public health departments began implementing statewide CCHD newborn screening 
programs in 2011.14,15 The earliest statewide programs were legislatively mandated, while 
other programs initiated over the 3 years subsequent to the RUSP addition came about 
through changes in state screening rules and regulations, with or without legislation or 
recommendations from state newborn screening advisory boards. Examples of these 
developments were summarized in a 2013 Issue Brief published online by the Association of 
Maternal and Child Health Programs: http://www.amchp.org/programsandtopics/CHILD-
HEALTH/projects/newborn-screen ing/Documents/
AMCHP_Screening_for_CCHD_Issue_Brief_FI NAL-Oct2013.pdf. Adding to the clinical 
evidence that led to the RUSP decision, results of a subsequent study indicated that CCHD 
screening appeared to be cost-effective, using modeled data and survey results from one of 
the early-adopting states.16 With the exception of just a few states, screening is either in the 
process of statewide implementation or has already been adopted statewide in U.S. birth 
hospitals; readers can find specific state status updates at http://www.aap.org/en-us/
advocacy-and-policy/state-advocacy/Documents/Newborn%20Screening%20for%20Critical
%20Congenital%20Heart%20Disease.pdf or links to state-specific websites for local 
mandates and guidance at http://www.babysfirsttest.org/newborn-screening/conditions/
critical-congenital-heart-disease-cchd. Even without mandates or regulations including 
CCHD screening on state panels, newborn screening programs in most of the states without 
a current screening requirement report that pulse oximetry screening is occurring (in a few 
such states, all hospitals are reportedly screening) (Hudson et al., submitted). In these states 
without requirements, the influence of the endorsements by national organizations such as 
AAP might be leading to screening practices that are based on “standards for care 
delivery.”17
Data collection by state health departments is sometimes also legislatively mandated, and 
with or without mandates many are attempting to collect information from birth hospitals 
(Hudson et al., submitted). Results from early statewide data collection efforts now have 
been published.14,15 As predicted, these studies demonstrated detection of otherwise 
Olney et al. Page 3
Semin Perinatol. Author manuscript; available in PMC 2016 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
unsuspected CCHD through pulse oximetry screening, which must be understood in the 
context of prenatal diagnosis and pre-screening clinical detection rates.
Prenatal and postnatal estimates of CCHD detection before 2011
Prenatal diagnosis of CCHD depends upon the recognition of structural heart defects via 
ultrasound or fetal echocardiography, typically during the second trimester. Guidelines put 
forth by the American Institute of Ultrasound in Medicine suggest that a basic cardiac 
examination should include a four-chamber view of the heart and, when technically feasible, 
views of the outflow tracts.18,19 Similar guidelines were issued by the American College of 
Obstetricians and Gynecologists.20 Further examination via fetal echocardiography is 
warranted if the ultrasound is abnormal, but also under circumstances such as a family 
history of congenital heart disease, presence of maternal diabetes, or use of in vitro 
fertilization.21
Some CCHD are more amenable to visualization through these methods than others. Using 
1997–2007 data from the Utah Birth Defect Network, Pinto et al.22 found that the defects 
most likely to be detected prenatally included those with abnormal four-chamber views, 
while defects exhibiting abnormal outflow tracts were much less likely to be detected 
prenatally. In a study of members of a large health maintenance organization (HMO) in 
California from 2005 to 2010, Levy et al.23 showed that women who received care from 
HMO clinics that had instituted a policy to examine outflow tracts during prenatal 
ultrasound had much higher prenatal diagnosis rates (59%) compared to HMO clinics that 
had not instituted such a policy (28%).
Given these challenges, it is not surprising that many studies have noted variation in the 
prenatal detection rates of CCHD (Table).22-26 Among the primary CCHD screening targets, 
hypoplastic left heart syndrome, for example, has been shown to be detected prenatally quite 
frequently, with estimates ranging from 53% to 88%.24,26 Other primary screening targets, 
such as total anomalous pulmonary venous return, are much less likely to be detected 
prenatally, with a few studies reporting no prenatally detected cases, though these studies 
often have a very small number of cases overall. Of the secondary screening targets, 
coarctation of the aorta is infrequently diagnosed before birth, with studies estimating that 
only 11–37% of cases have a prenatal diagnosis.24,26 Other secondary targets, such as 
double outlet right ventricle, seem to be diagnosed prenatally more frequently.
Maternal factors associated with increased rates of prenatal detection have included carrying 
multiple gestations, increased maternal age, maternal diabetes, and family history of CCHD, 
while non-Hispanic white maternal race/ethnicity and increased prepregnancy body-mass 
index have been associated with decreased rates of prenatal diagnosis.24,27 Infant/fetal 
characteristics associated with increased prenatal diagnosis have included the presence of 
other birth defects or chromosomal syndromes, as well as increasing complexity of CCHD. 
Improvements in ultrasonography and changes in guidelines to include both the four-
chamber view of the heart and outflow tracts may be responsible for some increase in 
overall prenatal detection of congenital heart defects seen since the mid-2000s.18,20,26
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Broad geographic as well as hospital-level variation in prenatal detection has likewise been 
noted.24,28,29 In a study of live born infants with “a single morphologic right ventricle with 
systemic outflow obstruction” seen at 15 centers participating in the Pediatric Cardiac 
Network from 2005 to 2009, Atz et al.28 noted that prenatal diagnosis rates ranged by center 
from 59% to 85% and that centers that saw a higher volume of patients were more likely to 
have higher prenatal diagnosis rates. In a study of factors associated with maternal report of 
prenatal diagnosis of any congenital heart defect (i.e., not restricted to CCHD), Ailes et al.24 
found maternal residence to be one of the strongest predictors of maternal report of prenatal 
diagnosis. Even among select CCHD types in these maternal reports, such as hypoplastic left 
heart syndrome, there was a four-fold difference between the geographic location with the 
lowest prevalence of maternal report of prenatal diagnosis (21%) and highest (81%). 
Geographic variation in access to high-quality imaging technology and skilled ultrasound 
technicians might play a role in the geographic variation observed in prenatal detection. The 
Utah study by Pinto et al.,22 for instance, also noted that access to high-risk clinics increased 
the likelihood of having a prenatal diagnosis by 10-fold.
As mentioned above, the decision to add CCHD to the RUSP was motivated by the 
realization that prenatal detection was incomplete and so-called “late” postnatal detection of 
CCHD led to potentially preventable deaths and morbidity. In studies of pre-2011 data, 
however, variation exists in how “late” detection has been operationalized, with authors 
alternatively defining late diagnosis as diagnosis after birth hospital discharge, after 3 days 
of birth, or even at death.30-32 Late detection of a number of the primary CCHD screening 
targets is relatively low, with an estimated 0–16% of cases of hypoplastic left heart 
syndrome, dextro-transposition of the great arteries, and tricuspid atresia reported to be late 
detected (Table).26,31 Among secondary screening targets, cases of coarctation of the aorta 
were estimated in three studies to be late detected much more frequently, with study 
estimates ranging from 30% to 62% of cases.26,31,33 In these three studies, factors associated 
with the late detection were less often related to maternal characteristics and more so 
associated with CCHD type, nursery level of care, and presence/absence of extracardiac 
defects.
Data collection in the screening era
Going forward, there is a widespread interest in collecting national data that will examine 
the performance of pulse oximetry screening programs and the impact of these programs on 
the overall timing of CCHD detection. In the U.S., NBDPN programs continue to compile 
CCHD surveillance data. Many birth defects surveillance programs unfortunately do not 
have the capacity or authority to collect CCHD newborn screening results, or to do so in a 
timely fashion, which has led to a need for national collection of data specific to CCHD 
newborn screening program identification and quality improvement. These data are 
collected through a recently funded Health Resources and Services Administration initiative: 
the Newborn Screening Technical assistance and Evaluation Program (NewSTEPs).
NewSTEPs functions as a partnership between the Association of Public Health 
Laboratories and the Colorado School of Public Health and operates with the mission of 
supporting the highest quality for newborn screening systems by providing relevant, 
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accurate tools and resources, and facilitating collaboration between newborn screening 
partners for both dried blood spot and point-of-care newborn screening. This initiative builds 
on the previously funded HRSA efforts, extending data collection to CCHD screening 
activities as well.34 Previous efforts for data collection in point-of-care newborn screening 
through early hearing detection and intervention have been funded by CDC.35 Aggregate 
data collected by CDC has provided the evidence of improved screening and identification 
of infants with early hearing loss. These efforts have demonstrated that central data 
collection and surveillance by newborn screening programs can provide much needed data 
for local quality improvement, and point to the need for consistent definitions for newborn 
screening.
Quality improvement and monitoring in CCHD newborn screening requires high-quality 
data with consistent definitions across newborn screening programs, such as those set forth 
for NBDPN programs.2 NewSTEPs provides a web-based repository to collect data on 
newborn screening program policies, quality indicators related to newborn screening 
programs, and specific case-level information on infants diagnosed with CCHD. Data 
collected within the NewSTEPs data repository will be summarized and reports will be 
compiled internally and reviewed by a data review committee comprised of newborn 
screening program experts. Reports will be distributed and shared at the state, local, and 
national level, and aggregate reports will be available publically on the NewSTEPs website.
As mentioned above, the policy, or rules and regulations for CCHD newborn screening data 
collection at the state level vary widely across the nation. Some programs collect every pulse 
oximetry value for each screening, others collect aggregate data from birthing hospitals, and 
yet others practice no public health data collection, even though standards for such data 
collection have been recommended.36 In the absence of centralized state data collection, 
public health newborn screening programs are unable to evaluate the performance of the 
screen in a standardized and comparative manner. NewSTEPs has assembled the policies 
from all state newborn screening programs for both CCHD screening and data collection. 
Annual review of these policies by NewSTEPs staff in collaboration with the data review 
committee will be performed to assure accurate representation and will provide a robust 
assessment of the CCHD policies in the U.S. Harnessing these collective policy differences 
can enable programs to identify model practices across the nation and to advocate for 
improved data collection systems with the benefit of shared information. Policy practices 
will be publically available via the NewSTEPs website to support state, regional, and 
national policies.
In collaboration with newborn screening stakeholders, NewSTEPs has finalized a core set of 
quality indicators that encompass key areas of newborn screening activities, which can be 
found at http://www.newsteps.org. These indicators are consistent with national collection 
efforts required within the Newborn Screening Saves Lives Act (http://www.con gress.gov/
bill/113th-congress/house-bill/1281) and build off of previously developed indicators.37 
State newborn screening programs have secure access to the NewSTEPs repository to enter 
quality indicators on an annual basis. Metrics are tracked between newborn screening 
programs as well as longitudinally within each program, with reports issued at the state, 
regional, and national levels. Quality indicators specific to CCHD newborn screening 
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include: percentage of eligible infants screened for CCHD, number of infants who screened 
positive for CCHD, number of infants with CCHD identified by newborn screening, number 
of newborns with CCHD who were missed on the newborn screen, and the timing of 
screening activities (screen, follow-up, and diagnosis). These quality indicators related to 
CCHD will provide the first national summary data on CCHD newborn screening. Data will 
be available on all quality indicators in 2015 and will be disseminated publically via the 
NewSTEPs website and through state, regional, and national newborn screening 
stakeholders.
In addition to aggregate newborn screening quality indicators, the NewSTEPs data 
repository collects case-level data related to the newborns identified with CCHD, including 
the timing of the pulse oximetry testing, follow-up testing, and confirmation of diagnosis. 
Assessment of the certainty of the diagnosis using standardized public health surveillance 
case definitions will allow consistent comparisons across programs and over time. State 
level policies on local data collection vary, and some states are not currently authorized to 
collect point-of-care testing data for CCHD newborn screening. NewSTEPs will report 
aggregate data from states that have individual newborn data via the NewSTEPs website and 
through state, local, and national newborn screening stakeholders.
The activities of NewSTEPs have been reviewed by the Colorado Multiple Institutional 
Review Board and the Health and Human Services Office of Human Research Protection 
and have been determined to be non-human subject research. NewSTEPs offers strict 
privacy to newborn screening programs, with many layers of access, enabling programs to 
determine the extent of quality- and case-specific information they wish to share on a non-
aggregate level. Data dissemination and sharing will be done via national, regional, and 
local mechanisms, and oversight of all data sharing will be accomplished through the data 
review committee. All states are participating in the NewSTEPs data repository, and all 
sensitive data from states (quality indicators and case definitions) are collected from states 
through a memorandum of understanding. The NewSTEPs repository remains dynamic and 
evolving, with routine feedback incorporated from the newborn screening community.
NBDPN surveillance programs remain uniquely positioned to contribute population-based 
CCHD data. More than 40 states collect data that can be used to estimate rates of individual 
types of CCHD (Fig.), and surveys indicate that most also have the capabilities to examine 
mortality (including time trends) and links to support services, which will be important in 
the evaluation of the impact of early identification.2,5,38 These surveys also indicate that 
some programs are also capable of evaluating interventions and morbidities associated with 
CCHD. Some programs should be (and have been) able to distinguish between detection 
along a continuum of key time periods: prenatal diagnoses, clinical detection in the pre-
screening period shortly after birth, and newborn screening-related diagnoses.15 Another 
important role of statewide surveillance programs will be to ascertain missed cases, either 
those children who were not diagnosed prenatally or somehow avoided screening in a 
newborn nursery, or true false negatives: failures of the screening algorithm itself or its 
application and interpretation.39,40 Birth defects programs already systematically ascertain 
CCHD cases identified clinically or through newborn screening, through a combination of 
active and passive methods.2 New Jersey has provided a model for ascertaining pulse 
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oximetry results with the use of a diagnostic code for failed screens, combined with linkage 
to reported CCHD cases to identify missed screens.15
Ultimately, the goal of early identification of CCHD will be not only to decrease mortality 
and other short-term adverse outcomes, but also to have long-term improvements in quality 
of life and morbidities for affected individuals. As noted above, birth defects surveillance 
systems have varying capabilities to measure some of these endpoints. A new public health 
priority is to evaluate long-term outcomes among older children and even adults with 
congenital heart defects, and pilot projects have been funded to link databases and do 
longitudinal surveillance and research.41,42 These projects, which are slated to be expanded 
in the future, can potentially examine covariates such as the timing of diagnosis along the 
continuum mentioned above; locations of birth and surgical interventions; and types and 
timings of all interventions.
Discussion/comment
National implementation of CCHD newborn screening has progressed rapidly since 2011, 
and while outcome trend data are still forthcoming, this public health program has promising 
potential to decrease infant mortality from these relatively common birth defects. Prenatal 
detection has become a significant contributor to early identification of CCHD. As long as 
disparities in use of prenatal ultrasound exist, due to factors such as location of maternal 
residence and access to high-risk clinics, CCHD newborn screening will provide an 
important safety net for early diagnosis across all populations.43
As with any new public health program, newborn screening data collection, including long-
term follow-up, will be essential to monitor the progress of implementation and will need to 
be ongoing for continuous quality improvement.40,44 Unlike traditional screening for 
disorders detectable in newborn blood spots, which are collected primarily in hospitals but 
analyzed in central laboratories, there are particular challenges for point-of-care newborn 
screening programs.17 These challenges include practical issues such as training and use of 
standardized algorithms in a variety of settings with multiple health care providers, as well 
as data collection issues that ideally need to occur both at the clinical level as well as 
involving public health.36
As detailed above, CCHD data surveillance is ongoing and expanding and the NewSTEPs 
data collection program has also begun. With the results of initial CCHD screening 
experiences, one particular research need would be to evaluate and optimize the algorithms 
used for pulse oximetry screening. To do so, efforts have begun to analyze case-level pulse 
oximetry data, and additional projects will require special data collection protocols beyond 
the projects outline above, ideally also incorporating false negative information with the 
collaboration of birth defects surveillance programs.40,45 Of particular interest to 
neonatologists, there are also data needs for screening protocols in neonatal intensive care 
units (NICUs). Many infants in NICUs have already been identified with CCHD through 
prenatal diagnosis, and others are monitored intensively with pulse oximetry. Since NICU 
oximetry is not necessarily done systematically, incorporating comparisons of pre- and post-
ductal oxygen saturation levels or making special provisions for infants treated with oxygen, 
Olney et al. Page 8
Semin Perinatol. Author manuscript; available in PMC 2016 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
some neonatologists have proposed specific protocols for screening NICU infants.46 
Screening can be similarly problematic in nurseries that are located at moderate or high 
altitudes where baseline saturation levels in normal newborns are understandably lower, so 
investigators in such settings have proposed modified algorithms and started collecting data 
with these protocols.47 Clearly, evidence-based recommendations for special settings will 
require more CCHD data.
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Summary
• Nearly 1% of newborn infants have congenital heart defects, and approximately 
one-quarter of those defects are in the CCHD category. Infant deaths have 
occurred most commonly with hypoplastic left heart syndrome, transposition of 
the great arteries, and tetralogy of Fallot. Pulse oximetry screening of newborns 
to prevent unexpected deaths has been well-studied.
• Based on evidence reviews, in 2011 CCHD screening was added to the U.S. 
Recommended Uniform Screening Panel for newborns. With a few state 
exceptions, screening is either in the process of statewide implementation or has 
already been adopted statewide in birth hospitals.
• There have been increases in overall prenatal detection rates of congenital heart 
defects seen since the mid-2000s; defect-specific, maternal, and geographic 
factors are associated with variations in prenatal detection, so CCHD newborn 
screening provides a population-wide safety net for early diagnosis.
• Birth defects surveillance programs are collecting data to examine current rates 
of CCHD detection through prenatal diagnoses, clinical detection in the pre-
screening period shortly after birth, and newborn screening-related diagnoses, as 
well as long-term follow-up data to examine outcomes in older children and 
adults.
• A recently funded program (NewSTEPs) has provided a web-based repository to 
collect data on newborn screening program policies, quality indicators related to 
newborn screening programs, and specific case-level information on infants 
with CCHD.
• Current research related to CCHD newborn screening focuses on evaluating and 
refining pulse oximetry algorithms and developing protocols for special 
populations (e.g., in NICUs and at moderate-to-high altitudes).
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Fig. 
Pooled birth prevalence among live births of primary critical congenital heart defects 
(CCHD) screening targets, by CCHD type, among population-based birth defects 
surveillance systems that use active case finding methodologies, United States, 2005–2009. 
The exact years and number of programs included (range: 11–16) vary by defect. Pooled 
prevalence was calculated by dividing the total number of cases across programs by total 
number of combined live births. (Adapted from Mai et al.2)
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